Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.
Aged
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cluster Analysis
Female
Humans
Longitudinal Studies
Male
Middle Aged
Neoplasm Staging
Neoplasms
/ complications
Patient Reported Outcome Measures
Peripheral Nervous System Diseases
/ diagnosis
Public Health Surveillance
Quality of Life
Surveys and Questionnaires
Symptom Assessment
Cancer
Chemotherapy-induced peripheral neuropathy
Patient-reported outcome
Symptom clusters
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
27 Nov 2019
27 Nov 2019
Historique:
received:
12
03
2019
accepted:
11
11
2019
entrez:
29
11
2019
pubmed:
30
11
2019
medline:
4
4
2020
Statut:
epublish
Résumé
Chemotherapy-induced peripheral neuropathy (CIPN) is common among cancer patients treated with neurotoxic chemotherapy agents. Better knowledge on symptom clusters of CIPN may help improve symptom management in clinical practice. This study aimed to identify symptom clusters of CIPN and to map their trajectories before initiation of chemotherapy to 12-month follow-up. A secondary analysis of a longitudinal dataset was conducted using principal component approach. The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires Core 30 and CIPN 20 were used to measure symptom clusters of CIPN in patients with mixed cancer diagnosis across 10 time points over 12 months. Sample size in each assessment point ranged from 118 to 343 participants. Four CIPN symptom clusters were identified, including a clear sensory neuropathy symptom cluster, a mixed motor-sensory neuropathy symptom cluster, a mixed sensorimotor neuropathy symptom cluster, and a less clear autonomic neuropathy symptom cluster. The core symptoms in each symptom cluster were mostly stable while the secondary symptoms changed over time. The analysis suggests that CIPN is predominantly a sensory neuropathy with no evidence of a pure motor dysfunction but with mixed motor-related and autonomic changes accompanying sensory dysfunctions over time. Future symptom management strategies can be designed based on the morphology of CIPN.
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy-induced peripheral neuropathy (CIPN) is common among cancer patients treated with neurotoxic chemotherapy agents. Better knowledge on symptom clusters of CIPN may help improve symptom management in clinical practice. This study aimed to identify symptom clusters of CIPN and to map their trajectories before initiation of chemotherapy to 12-month follow-up.
METHODS
METHODS
A secondary analysis of a longitudinal dataset was conducted using principal component approach. The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires Core 30 and CIPN 20 were used to measure symptom clusters of CIPN in patients with mixed cancer diagnosis across 10 time points over 12 months.
RESULTS
RESULTS
Sample size in each assessment point ranged from 118 to 343 participants. Four CIPN symptom clusters were identified, including a clear sensory neuropathy symptom cluster, a mixed motor-sensory neuropathy symptom cluster, a mixed sensorimotor neuropathy symptom cluster, and a less clear autonomic neuropathy symptom cluster. The core symptoms in each symptom cluster were mostly stable while the secondary symptoms changed over time.
CONCLUSIONS
CONCLUSIONS
The analysis suggests that CIPN is predominantly a sensory neuropathy with no evidence of a pure motor dysfunction but with mixed motor-related and autonomic changes accompanying sensory dysfunctions over time. Future symptom management strategies can be designed based on the morphology of CIPN.
Identifiants
pubmed: 31775665
doi: 10.1186/s12885-019-6352-3
pii: 10.1186/s12885-019-6352-3
pmc: PMC6882224
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1151Subventions
Organisme : This study was supported by a Polytechnic University Direct grant (in HK) and an NCIS Seed Funding Grant, National Medical Research Council (Singapore).
ID : n/a
Références
Ann Oncol. 2013 Feb;24(2):454-62
pubmed: 22910842
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28954296
J Pain Symptom Manage. 2018 Jan;55(1):39-55
pubmed: 28838866
Ann Neurol. 2017 Jun;81(6):772-781
pubmed: 28486769
J Cancer Surviv. 2018 Apr;12(2):234-245
pubmed: 29159795
CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37
pubmed: 24590861
J Clin Nurs. 2018 Feb;27(3-4):516-545
pubmed: 28859255
Value Health. 2013 Jul-Aug;16(5):848-54
pubmed: 23947980
Clin Cancer Res. 2012 Jun 1;18(11):3180-7
pubmed: 22496202
J Neurooncol. 2006 Mar;77(1):79-87
pubmed: 16132528
Eur J Cancer Care (Engl). 2017 Sep;26(5):null
pubmed: 26786536
J Pain Symptom Manage. 2017 Aug;54(2):204-218.e2
pubmed: 28063866
J Clin Oncol. 2015 Oct 20;33(30):3416-22
pubmed: 26282635
J Pain Symptom Manage. 2015 Jun;49(6):1025-34
pubmed: 25582681
Qual Life Res. 2017 Nov;26(11):2999-3010
pubmed: 28634676
J Pain Symptom Manage. 2010 May;39(5):847-58
pubmed: 20226621
Eur J Cancer. 2002 Mar;38 Suppl 4:S125-33
pubmed: 11858978
Eur J Oncol Nurs. 2018 Oct;36:135-141
pubmed: 30322504
J Pain Symptom Manage. 2014 Mar;47(3):566-78
pubmed: 24035068
BMC Cancer. 2019 Feb 8;19(1):132
pubmed: 30736741
Cancer. 2010 Jul 15;116(14):3348-56
pubmed: 20564075
J Clin Oncol. 2017 Aug 10;35(23):2604-2612
pubmed: 28586243
Curr Opin Support Palliat Care. 2013 Mar;7(1):45-53
pubmed: 23196378
Asia Pac J Clin Oncol. 2019 Feb;15(1):56-62
pubmed: 29873180
J Peripher Nerv Syst. 2018 Jun;23(2):129-133
pubmed: 29696771
Clin Neurophysiol. 2017 Jul;128(7):1166-1175
pubmed: 28511129
Support Care Cancer. 2015 Nov;23(11):3373-84
pubmed: 26111954
Asian Nurs Res (Korean Soc Nurs Sci). 2008 Mar;2(1):17-24
pubmed: 25031108
Gynecol Oncol. 2017 Apr;145(1):148-153
pubmed: 28202195
Cancer Nurs. 2005 Jul-Aug;28(4):270-82; quiz 283-4
pubmed: 16046888
Palliat Med. 2010 Jun;24(4):373-85
pubmed: 20507866
Support Care Cancer. 2014 Aug;22(8):2261-9
pubmed: 24789421
Ann Oncol. 2008 Dec;19(12):2053-60
pubmed: 18653703
Support Care Cancer. 2012 Mar;20(3):625-32
pubmed: 21479990
Eur J Oncol Nurs. 2018 Feb;32:1-11
pubmed: 29353626